The introduction of imatinib and the following second generation tyrosine kinase inhibitors (TKIs) dasatinib and nilotinib, targeting the pathognomonic BCR::ABL1 fusion protein, has revolutionized chronic myeloid leukemia (CML) treatment. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.